Cargando…

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial

BACKGROUND: Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50–60% of patients and has a 5-year event-free survival of 75–85%....

Descripción completa

Detalles Bibliográficos
Autores principales: Goschzik, Tobias, Schwalbe, Edward C, Hicks, Debbie, Smith, Amanda, zur Muehlen, Anja, Figarella-Branger, Dominique, Doz, François, Rutkowski, Stefan, Lannering, Birgitta, Pietsch, Torsten, Clifford, Steven C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262170/
https://www.ncbi.nlm.nih.gov/pubmed/30392813
http://dx.doi.org/10.1016/S1470-2045(18)30532-1
_version_ 1783375051261739008
author Goschzik, Tobias
Schwalbe, Edward C
Hicks, Debbie
Smith, Amanda
zur Muehlen, Anja
Figarella-Branger, Dominique
Doz, François
Rutkowski, Stefan
Lannering, Birgitta
Pietsch, Torsten
Clifford, Steven C
author_facet Goschzik, Tobias
Schwalbe, Edward C
Hicks, Debbie
Smith, Amanda
zur Muehlen, Anja
Figarella-Branger, Dominique
Doz, François
Rutkowski, Stefan
Lannering, Birgitta
Pietsch, Torsten
Clifford, Steven C
author_sort Goschzik, Tobias
collection PubMed
description BACKGROUND: Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50–60% of patients and has a 5-year event-free survival of 75–85%. Within standard-risk medulloblastoma, patients in the WNT subgroup are established as having a favourable prognosis; however, outcome prediction for the remaining majority of patients is imprecise. We sought to identify novel prognostic biomarkers to enable improved risk-adapted therapies. METHODS: The HIT-SIOP PNET 4 trial recruited 338 patients aged 4–21 years with medulloblastoma between Jan 1, 2001, and Dec 31, 2006, in 120 treatment institutions in seven European countries to investigate hyperfractionated radiotherapy versus standard radiotherapy. In this retrospective analysis, we assessed the remaining tumour samples from patients in the HIT-SIOP PNET 4 trial (n=136). We assessed the clinical behaviour of the molecularly defined WNT and SHH subgroups, and identified novel independent prognostic markers and models for standard-risk patients with non-WNT/non-SHH disease. Because of the scarcity and low quality of available genomic material, we used a mass spectrometry-minimal methylation classifier assay (MS-MIMIC) to assess methylation subgroup and a molecular inversion probe array to detect genome-wide copy number aberrations. Prognostic biomarkers and models identified were validated in an independent, demographically matched cohort (n=70) of medulloblastoma patients with non-WNT/non-SHH standard-risk disease treated with conventional therapies (maximal surgical resection followed by adjuvant craniospinal irradiation [all patients] and chemotherapy [65 of 70 patients], at UK Children's Cancer and Leukaemia Group and European Society for Paediatric Oncology (SIOPE) associated treatment centres between 1990 and 2014. These samples were analysed by Illumina 450k DNA methylation microarray. HIT-SIOP PNET 4 is registered with ClinicalTrials.gov, number NCT01351870. FINDINGS: We analysed methylation subgroup, genome-wide copy number aberrations, and mutational features in 136 assessable tumour samples from the HIT-SIOP PNET 4 cohort, representing 40% of the 338 patients in the trial cohort. This cohort of 136 samples consisted of 28 (21%) classified as WNT, 17 (13%) as SHH, and 91 (67%) as non-WNT/non-SHH (we considered Group3 and Group4 medulloblastoma together in our analysis because of their similar molecular and clinical features). Favourable outcomes for WNT tumours were confirmed in patients younger than 16 years, and all relapse events in SHH (four [24%] of 17) occurred in patients with TP53 mutation (TP53(mut)) or chromosome 17p loss. A novel whole chromosomal aberration signature associated with increased ploidy and multiple non-random whole chromosomal aberrations was identified in 38 (42%) of the 91 samples from patients with non-WNT/non-SHH medulloblastoma in the HIT-SIOP PNET 4 cohort. Biomarkers associated with this whole chromosomal aberration signature (at least two of chromosome 7 gain, chromosome 8 loss, and chromosome 11 loss) predicted favourable prognosis. Patients with non-WNT/non-SHH medulloblastoma could be reclassified by these markers as having favourable-risk or high-risk disease. In patients in the HIT-SIOP PNET4 cohort with non-WNT/non-SHH medulloblastoma, with a median follow-up of 6·7 years (IQR 5·8–8·2), 5-year event-free survival was 100% in the favourable-risk group and 68% (95% CI 57·5–82·7; p=0·00014) in the high-risk group. In the validation cohort, with a median follow-up of 5·6 years (IQR 3·1–8·1), 5-year event-free survival was 94·7% (95% CI 85·2–100) in the favourable-risk group and 58·6% (95% CI 45·1–76·1) in the high-risk group (hazard ratio 9·41, 95% CI 1·25–70·57; p=0·029). Our comprehensive molecular investigation identified subgroup-specific risk models which allowed 69 (51%) of 134 accessible patients from the standard-risk medulloblastoma HIT-SIOP PNET 4 cohort to be assigned to a favourable-risk group. INTERPRETATION: We define a whole chromosomal signature that allows the assignment of non-WNT/non-SHH medulloblastoma patients normally classified as standard-risk into favourable-risk and high-risk categories. In addition to patients younger than 16 years with WNT tumours, patients with non-WNT/non-SHH tumours with our defined whole chromosomal aberration signature and patients with SHH-TP53(wild-type) tumours should be considered for therapy de-escalation in future biomarker-driven, risk-adapted clinical trials. The remaining subgroups of patients with high-risk medulloblastoma might benefit from more intensive therapies. FUNDING: Cancer Research UK, Swedish Childhood Cancer Foundation, French Ministry of Health/French National Cancer Institute, and the German Children's Cancer Foundation.
format Online
Article
Text
id pubmed-6262170
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lancet Pub. Group
record_format MEDLINE/PubMed
spelling pubmed-62621702018-12-06 Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial Goschzik, Tobias Schwalbe, Edward C Hicks, Debbie Smith, Amanda zur Muehlen, Anja Figarella-Branger, Dominique Doz, François Rutkowski, Stefan Lannering, Birgitta Pietsch, Torsten Clifford, Steven C Lancet Oncol Article BACKGROUND: Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50–60% of patients and has a 5-year event-free survival of 75–85%. Within standard-risk medulloblastoma, patients in the WNT subgroup are established as having a favourable prognosis; however, outcome prediction for the remaining majority of patients is imprecise. We sought to identify novel prognostic biomarkers to enable improved risk-adapted therapies. METHODS: The HIT-SIOP PNET 4 trial recruited 338 patients aged 4–21 years with medulloblastoma between Jan 1, 2001, and Dec 31, 2006, in 120 treatment institutions in seven European countries to investigate hyperfractionated radiotherapy versus standard radiotherapy. In this retrospective analysis, we assessed the remaining tumour samples from patients in the HIT-SIOP PNET 4 trial (n=136). We assessed the clinical behaviour of the molecularly defined WNT and SHH subgroups, and identified novel independent prognostic markers and models for standard-risk patients with non-WNT/non-SHH disease. Because of the scarcity and low quality of available genomic material, we used a mass spectrometry-minimal methylation classifier assay (MS-MIMIC) to assess methylation subgroup and a molecular inversion probe array to detect genome-wide copy number aberrations. Prognostic biomarkers and models identified were validated in an independent, demographically matched cohort (n=70) of medulloblastoma patients with non-WNT/non-SHH standard-risk disease treated with conventional therapies (maximal surgical resection followed by adjuvant craniospinal irradiation [all patients] and chemotherapy [65 of 70 patients], at UK Children's Cancer and Leukaemia Group and European Society for Paediatric Oncology (SIOPE) associated treatment centres between 1990 and 2014. These samples were analysed by Illumina 450k DNA methylation microarray. HIT-SIOP PNET 4 is registered with ClinicalTrials.gov, number NCT01351870. FINDINGS: We analysed methylation subgroup, genome-wide copy number aberrations, and mutational features in 136 assessable tumour samples from the HIT-SIOP PNET 4 cohort, representing 40% of the 338 patients in the trial cohort. This cohort of 136 samples consisted of 28 (21%) classified as WNT, 17 (13%) as SHH, and 91 (67%) as non-WNT/non-SHH (we considered Group3 and Group4 medulloblastoma together in our analysis because of their similar molecular and clinical features). Favourable outcomes for WNT tumours were confirmed in patients younger than 16 years, and all relapse events in SHH (four [24%] of 17) occurred in patients with TP53 mutation (TP53(mut)) or chromosome 17p loss. A novel whole chromosomal aberration signature associated with increased ploidy and multiple non-random whole chromosomal aberrations was identified in 38 (42%) of the 91 samples from patients with non-WNT/non-SHH medulloblastoma in the HIT-SIOP PNET 4 cohort. Biomarkers associated with this whole chromosomal aberration signature (at least two of chromosome 7 gain, chromosome 8 loss, and chromosome 11 loss) predicted favourable prognosis. Patients with non-WNT/non-SHH medulloblastoma could be reclassified by these markers as having favourable-risk or high-risk disease. In patients in the HIT-SIOP PNET4 cohort with non-WNT/non-SHH medulloblastoma, with a median follow-up of 6·7 years (IQR 5·8–8·2), 5-year event-free survival was 100% in the favourable-risk group and 68% (95% CI 57·5–82·7; p=0·00014) in the high-risk group. In the validation cohort, with a median follow-up of 5·6 years (IQR 3·1–8·1), 5-year event-free survival was 94·7% (95% CI 85·2–100) in the favourable-risk group and 58·6% (95% CI 45·1–76·1) in the high-risk group (hazard ratio 9·41, 95% CI 1·25–70·57; p=0·029). Our comprehensive molecular investigation identified subgroup-specific risk models which allowed 69 (51%) of 134 accessible patients from the standard-risk medulloblastoma HIT-SIOP PNET 4 cohort to be assigned to a favourable-risk group. INTERPRETATION: We define a whole chromosomal signature that allows the assignment of non-WNT/non-SHH medulloblastoma patients normally classified as standard-risk into favourable-risk and high-risk categories. In addition to patients younger than 16 years with WNT tumours, patients with non-WNT/non-SHH tumours with our defined whole chromosomal aberration signature and patients with SHH-TP53(wild-type) tumours should be considered for therapy de-escalation in future biomarker-driven, risk-adapted clinical trials. The remaining subgroups of patients with high-risk medulloblastoma might benefit from more intensive therapies. FUNDING: Cancer Research UK, Swedish Childhood Cancer Foundation, French Ministry of Health/French National Cancer Institute, and the German Children's Cancer Foundation. Lancet Pub. Group 2018-12 /pmc/articles/PMC6262170/ /pubmed/30392813 http://dx.doi.org/10.1016/S1470-2045(18)30532-1 Text en © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Goschzik, Tobias
Schwalbe, Edward C
Hicks, Debbie
Smith, Amanda
zur Muehlen, Anja
Figarella-Branger, Dominique
Doz, François
Rutkowski, Stefan
Lannering, Birgitta
Pietsch, Torsten
Clifford, Steven C
Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
title Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
title_full Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
title_fullStr Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
title_full_unstemmed Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
title_short Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
title_sort prognostic effect of whole chromosomal aberration signatures in standard-risk, non-wnt/non-shh medulloblastoma: a retrospective, molecular analysis of the hit-siop pnet 4 trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262170/
https://www.ncbi.nlm.nih.gov/pubmed/30392813
http://dx.doi.org/10.1016/S1470-2045(18)30532-1
work_keys_str_mv AT goschziktobias prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT schwalbeedwardc prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT hicksdebbie prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT smithamanda prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT zurmuehlenanja prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT figarellabrangerdominique prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT dozfrancois prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT rutkowskistefan prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT lanneringbirgitta prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT pietschtorsten prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial
AT cliffordstevenc prognosticeffectofwholechromosomalaberrationsignaturesinstandardrisknonwntnonshhmedulloblastomaaretrospectivemolecularanalysisofthehitsioppnet4trial